-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 21, 2021, the international pharmaceutical giants began to announce the first half of the financial report.
China has now become the world's second largest market for the new heart failure drug Entresto (sacubatril valsartan, Chinese product name: Nuoxinto), with sales accounting for about a quarter of the drug's total sales outside the United States
Johnson & Johnson's second-quarter revenue reached 23.
(2) Pharmaceutical business: Revenue in the second quarter was US$12.
Divided by disease field: Immunology sales of US$4.
(3) Medical devices: Revenue in the second quarter was 7 billion US dollars, an increase of 58.
7%, mainly due to the recovery of the market after the weakening of the impact of covid-19, and the recovery of surgery, orthopedics, vision and intervention solutions
.
Summarize
Partly benefiting from the market recovery after the new crown epidemic was brought under control in the first half of the year, the two pharmaceutical giants have achieved very good results
.
congratulations!
Friends who need Johnson & Johnson and Novartis’s financial report PPT, please leave a message on the backstage of the Pharmaceutical Times official account and inform you of the documents and email addresses you are interested in
.
We will send them together today, for personal reference only for careful study
.
Pharmaceutical Times will continue to report in time
.
stay tuned!
Reference materials:
Reference materials:Novartis Financial Report
Novartis Financial ReportJohnson & Johnson Financial Report
Johnson & Johnson Financial Report Novartis 2021 semi-annual report: revenue of US$25.
4 billion, China revenue of US$1.
5 billion, sales of gene therapy Zolgensma increased by 69%, and Entresto increased by 46%
4 billion, China revenue of US$1.
5 billion, sales of gene therapy Zolgensma increased by 69%, and Entresto increased by 46%
Novartis semi-annual report: 2Q revenue increased by 14%, of which innovative drugs increased by 15%, generic drugs increased by 9%
Novartis semi-annual report: 2Q revenue increased by 14%, of which innovative drugs increased by 15%, generic drugs increased by 9%Heavy! Medical insurance helps heart failure: Sacubatril and valsartan enter the medical insurance catalog!
Heavy! Medical insurance helps heart failure: Sacubatril and valsartan enter the medical insurance catalog!Other public information
Other public information
